Renal denervation therapy beyond resistant hypertension

It is estimated that over one billion people worldwide are affected by hypertension (HTN) and that over nine million annual deaths can be attributed to complications of HTN such as myocardial infarction, stroke and renal disease. The prevalence of HTN is constantly rising and this trend is expected to continue unless appropriate measures are taken (1,2). Importantly, even very mild reductions in blood pressure were linked to a large effect on rates of cardiovascular events (3,4).